AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26545279 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care 2% lidocaine with 1:100,000 epinephrine (unbuffered)
Number of subjects: 20
Study 23025584 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (participants under stress)
Number of subjects: 106
Study 23025584 — intervention group
Group type: COMPARATOR
Intervention: No stress condition (participants not under stress)
Number of subjects: 106
Study 23025584 — intervention group
Group type: EXPERIMENTAL
Intervention: Confederate's drinking condition: alcohol
Number of subjects: 106
Study 23025584 — intervention group
Group type: COMPARATOR
Intervention: Confederate's drinking condition: soda
Number of subjects: 106
Study 21475968 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month school-based physical activity program
Number of subjects: 457
Study 21475968 — intervention group
Group type: COMPARATOR
Intervention: Observational group (control)
Number of subjects: 457
Study 18697778 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for lower TJC patients
Number of subjects: 2002
Study 18697778 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for higher TJC patients
Number of subjects: 2002
Study 18697778 — intervention group
Group type: COMPARATOR
Intervention: Control treatment for higher TJC patients
Number of subjects: 2002
Study 18697778 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for lower SJC patients
Number of subjects: 2002
Study 18697778 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment for higher SJC patients
Number of subjects: 2002
Study 18697778 — intervention group
Group type: COMPARATOR
Intervention: Control treatment for higher SJC patients
Number of subjects: 2002
Study 16860176 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine 35 microg/h
Number of subjects: 239
Study 16860176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine tablets (0.2 mg) as needed for breakthrough pain
Number of subjects: 239
Study 14501247 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the sacral nerve roots
Number of subjects: 0
Study 14501247 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation of the sacral nerve roots
Number of subjects: 0
Study 11025242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 43
Study 11025242 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 43
Study 9102740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 2 weeks
Number of subjects: 163
Study 9102740 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily for 2 weeks
Number of subjects: 163
Study 1423952 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA) performed 4-14 days after MI
Number of subjects: 87
Study 1423952 — intervention group
Group type: COMPARATOR
Intervention: No PTCA (medical therapy alone)
Number of subjects: 87
Study 3904378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine and diet
Number of subjects: 143
Study 3904378 — intervention group
Group type: COMPARATOR
Intervention: Placebo and diet
Number of subjects: 143
Study 31055857 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (1 g/kg body weight)
Number of subjects: 23
Study 31055857 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (1 g/kg body weight)
Number of subjects: 23
Study 31055857 — intervention group
Group type: COMPARATOR
Intervention: Calorie-free control
Number of subjects: 23
Study 29325236 — intervention group
Group type: EXPERIMENTAL
Intervention: relamorelin 100 μg subcutaneously daily
Number of subjects: 22
Study 29325236 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 27498268 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscope
Number of subjects: 86
Study 27498268 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 86
Study 25154378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 218
Study 23724879 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg·kg(‐1)·day(‐1) of caffeine
Number of subjects: 30
Study 23724879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (malt-dextrin)
Number of subjects: 30
Study 20835904 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise session (50-min on cycle-ergometer at 65% peak oxygen uptake)
Number of subjects: 34
Study 20835904 — intervention group
Group type: COMPARATOR
Intervention: Chronic exercise program (4 months)
Number of subjects: 34
Study 18311749 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal hormone therapy (PHT)
Number of subjects: 27347
Study 18311749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27347
Study 17156486 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculomotor capture task with irrelevant stimulus
Number of subjects: 23
Study 12681528 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (50 mg/kg t.i.d for 3 months)
Number of subjects: 35
Study 12681528 — intervention group
Group type: COMPARATOR
Intervention: NTX (50 mg/day for 3 months)
Number of subjects: 35
Study 10669272 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.75% plus NaCL 0.9% (Group I)
Number of subjects: 0
Study 10669272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% plus 0.150 mg clonidine (Group II)
Number of subjects: 0
Study 9074543 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG3 SPECT with a graduated dose of 20 mCi (minimum 2 mCi) of 99mTc‐MAG3
Number of subjects: 10
Study 9074543 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG3 SPECT
Number of subjects: 10
Study 9074543 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous injection of MAG3 and a diuretic (2-40 mg furosemide)
Number of subjects: 10
Study 8364134 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine nocte
Number of subjects: 0
Study 8364134 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine b.d.
Number of subjects: 0
Study 8364134 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine q.d.s.
Number of subjects: 0
Study 3714083 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyropramide (300 mg per diem for 3 days per os)
Number of subjects: 10
Study 3714083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29804023 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised exercise programme (12-week programme focusing on strength, balance, flexibility, and walking endurance)
Number of subjects: 15
Study 29804023 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised exercise programme
Number of subjects: 15
Study 26778744 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative warm up training using a virtual reality simulator
Number of subjects: 10
Study 26778744 — intervention group
Group type: COMPARATOR
Intervention: No warm up before surgery
Number of subjects: 10
Study 24942975 — intervention group
Group type: EXPERIMENTAL
Intervention: High beta-palmitate formula (HBP)
Number of subjects: 63
Study 24942975 — intervention group
Group type: COMPARATOR
Intervention: Low beta-palmitate formula (LBP)
Number of subjects: 63
Study 24942975 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding (BF)
Number of subjects: 63
Study 23275364 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (4 g/day)
Number of subjects: 31
Study 23275364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21986122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 U/kg)
Number of subjects: 0
Study 21986122 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 0
Study 18201206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg + Glimepiride (GLIM) 3 mg
Number of subjects: 0
Study 18201206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 8 mg + Glimepiride (GLIM) 3 mg
Number of subjects: 0
Study 18201206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Glimepiride (GLIM) 3 mg
Number of subjects: 0
Study 18201206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg + Glimepiride (GLIM) (low-dose prior to uptitration)
Number of subjects: 0
Study 18201206 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (GLIM) monotherapy
Number of subjects: 0
Study 16516304 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 10
Study 16516304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12716264 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepirone-ER (20-80 mg/day)
Number of subjects: 209
Study 12716264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 11584879 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction condition
Number of subjects: 0
Study 11584879 — intervention group
Group type: COMPARATOR
Intervention: No-distraction condition
Number of subjects: 0
Study 9196146 — intervention group
Group type: EXPERIMENTAL
Intervention: Truquant BR radioimmunoassay (RIA) for CA 27.29 antigen
Number of subjects: 166
Study 1589233 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 20
Study 1589233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1589233 — intervention group
Group type: EXPERIMENTAL
Intervention: No choice
Number of subjects: 20
Study 3091627 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ng/kg X min GHRH
Number of subjects: 6
Study 3091627 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ng/kg X min GHRH
Number of subjects: 6
Study 3091627 — intervention group
Group type: COMPARATOR
Intervention: 0.15 M NaCl (Control)
Number of subjects: 6
Study 29656488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-focused MNCH (intensified interpersonal counselling, community mobilization, distribution of free micronutrient supplements, and weight-gain monitoring)
Number of subjects: 0
Study 29656488 — intervention group
Group type: COMPARATOR
Intervention: Standard MNCH (antenatal care with standard nutrition counselling)
Number of subjects: 0
Study 26756540 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive intervertebral neck manipulation and neck range of motion exercises
Number of subjects: 22
Study 26756540 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 22
Study 23980743 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-temperature atmospheric pressure plasma (LTAPP)
Number of subjects: 42
Study 23980743 — intervention group
Group type: COMPARATOR
Intervention: 2.5% NaOCl (positive control)
Number of subjects: 42
Study 23980743 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous ozone
Number of subjects: 42
Study 23980743 — intervention group
Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 42
Study 22402418 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-20mg/day) started within 12 hours after admission for two weeks
Number of subjects: 50
Study 22402418 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 22402418 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-20mg/day)
Number of subjects: 50
Study 22402418 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin group
Number of subjects: 50
Study 20445152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task-based exercise training
Number of subjects: 61
Study 20445152 — intervention group
Group type: COMPARATOR
Intervention: Unspecific low-intensity exercise (Control Group)
Number of subjects: 61
Study 18331218 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normobaric hypoxia (Hy; n = 10)
Number of subjects: 17
Study 18331218 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (Con; n = 7)
Number of subjects: 17
Study 20553655 — intervention group
Group type: EXPERIMENTAL
Intervention: SUD patients who died by suicide (n = 854)
Number of subjects: 854
Study 20553655 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent psychopathology in SUD patients who died by suicide (n = 854)
Number of subjects: 854
Study 16356186 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (3 individual sessions and 1 group session)
Number of subjects: 110
Study 16356186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study 11487258 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg o.d.)
Number of subjects: 347
Study 11487258 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg o.d.)
Number of subjects: 347
Study 11487258 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole and Tamoxifen (1 mg and 20 mg o.d. respectively)
Number of subjects: 347
Study 11487258 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 347
Study 11487258 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 347
Study 11487258 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole and Tamoxifen
Number of subjects: 347
Study 9740099 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual motor activation task
Number of subjects: 6
Study 9740099 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) administration
Number of subjects: 6
Study 8310485 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin 12,000 IU (Group 2)
Number of subjects: 114
Study 8310485 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin 24,000 IU (Group 3)
Number of subjects: 114
Study 8310485 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 1)
Number of subjects: 114
Study 3140862 — intervention group
Group type: EXPERIMENTAL
Intervention: nalmefene 0.4 mg/70 kg
Number of subjects: 0
Study 3140862 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone 0.4 mg/70 kg (low dose)
Number of subjects: 0
Study 3140862 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone 1.6 mg/70 kg (high dose)
Number of subjects: 0
Study 3140862 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 0
Study 31111682 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score methods for covariate adjustment
Number of subjects: 0
Study 31111682 — intervention group
Group type: COMPARATOR
Intervention: Conventional regression approach
Number of subjects: 0
Study 30157896 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 monthly ART supply through community ART groups (CAGs)
Number of subjects: 5760
Study 30157896 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 monthly ART supply through community ART distribution points (CAD)
Number of subjects: 5760
Study 30157896 — intervention group
Group type: COMPARATOR
Intervention: 3 monthly ART supply at facilities
Number of subjects: 5760
Study 26895633 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR and PDLSC sheets in combination with Bio‐oss(®) (Cell group)
Number of subjects: 30
Study 26895633 — intervention group
Group type: COMPARATOR
Intervention: GTR and Bio‐oss(®) without stem cells (Control group)
Number of subjects: 30
Study 24013470 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted TME with ASP
Number of subjects: 80
Study 24013470 — intervention group
Group type: COMPARATOR
Intervention: Open TME with ASP
Number of subjects: 80
Study 22785264 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-PACT (School-Based Preventive Asthma Care Technology)
Number of subjects: 100
Study 22785264 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 20618595 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercise (daily from 18 weeks of gestation to the end of pregnancy)
Number of subjects: 124
Study 20618595 — intervention group
Group type: COMPARATOR
Intervention: Walking exercise (daily from 18 weeks of gestation to the end of pregnancy)
Number of subjects: 124
Study 17485435 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 38
Study 17485435 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anaesthesia
Number of subjects: 38
Study 15942292 — intervention group
Group type: EXPERIMENTAL
Intervention: B7 gene polymorphisms (CD80 and CD86)
Number of subjects: 146
Study 11795727 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 N tension during fixation
Number of subjects: 50
Study 11795727 — intervention group
Group type: COMPARATOR
Intervention: 50 N tension during fixation
Number of subjects: 50
Study 11795727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 10696686 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (Plavix)
Number of subjects: 0
Study 10696686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (Ticlid)
Number of subjects: 0
Study 10696686 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 7673544 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patches
Number of subjects: 34
Study 7673544 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 34
Study 2209306 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated tuning fork
Number of subjects: 189
Study 7468948 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg terbutaline sulphate aerosol via a 10 cm tube extension
Number of subjects: 32
Study 7468948 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg salbutamol sulphate via conventional pressurized aerosol
Number of subjects: 32
Study 31242534 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctive estimates
Number of subjects: 0
Study 31242534 — intervention group
Group type: EXPERIMENTAL
Intervention: Disjunctive estimates
Number of subjects: 0
Study 31242534 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint event probabilities
Number of subjects: 0
Study 31242534 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctive-less likely probability difference
Number of subjects: 0
Study 27000391 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 135
Study 27000391 — intervention group
Group type: COMPARATOR
Intervention: Non-edoxaban (control group)
Number of subjects: 135
Study 25989606 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day memantine (MMT+M)
Number of subjects: 134
Study 25989606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MMT+P)
Number of subjects: 134
Study 24604528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit2Quit intervention (10 exercise telephone counseling sessions over 6 months) plus usual care (behavioral counseling and nicotine replacement therapy)
Number of subjects: 906
Study 24604528 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 906
Study 21121983 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 μg/day
Number of subjects: 52
Study 21121983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 18950932 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU ablation of primary breast cancer, followed by modified radical mastectomy within 1-2 weeks.
Number of subjects: 48
Study 18950932 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy (control group).
Number of subjects: 48
Study 18950932 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU group (compared to control group).
Number of subjects: 48
Study 17335331 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM study (RCT)
Number of subjects: 247
Study 17335331 — intervention group
Group type: COMPARATOR
Intervention: Phenomenology study
Number of subjects: 247
Study 17335331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 247
Study 15303246 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 units of alcohol consumed >90 min previously
Number of subjects: 20
Study 15303246 — intervention group
Group type: COMPARATOR
Intervention: Nil alcohol
Number of subjects: 20
Study 12375667 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (3 microg/kg) plus dexamethasone (8 mg orally)
Number of subjects: 52
Study 12375667 — intervention group
Group type: COMPARATOR
Intervention: G-CSF (12 microg/kg) alone
Number of subjects: 52
Study 10530096 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral-B 3D Plaque Remover
Number of subjects: 35
Study 10530096 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 35
Study 8090844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense endurance exercise training for 12 weeks
Number of subjects: 11
Study 8090844 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 11
Study 2574842 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon) therapy
Number of subjects: 36
Study 2574842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 780403 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 780403 — intervention group
Group type: EXPERIMENTAL
Intervention: Papase
Number of subjects: 0
Study 31647125 — intervention group
Group type: COMPARATOR
Intervention: Attention control group activities
Number of subjects: 148
Study 31647125 — intervention group
Group type: COMPARATOR
Intervention: Conversation (20.1% of visit time)
Number of subjects: 148
Study 31647125 — intervention group
Group type: COMPARATOR
Intervention: Playing games (18.7% of visit time)
Number of subjects: 148
Study 29208786 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants
Number of subjects: 10
Study 29208786 — intervention group
Group type: COMPARATOR
Intervention: Conventional implants
Number of subjects: 10
Study 25479585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate 20 mg in 500 mL of 5% glucose solution
Number of subjects: 818
Study 25479585 — intervention group
Group type: COMPARATOR
Intervention: Control group (500 mL of 5% glucose solution)
Number of subjects: 818
Study 22883321 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with fat graft
Number of subjects: 25
Study 22883321 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich fibrin (PRF) combined with fat graft
Number of subjects: 25